Postvaccination | ||||||
---|---|---|---|---|---|---|
Dependent Variables | Prevaccination | 4 Wk | 8 Wk | 12 Wk | 6 Mo | 9 Mo |
Thrice BCG Group | ||||||
PEFR (L/min) | 360.5 ± 61.1 | 403.5 ± 71.9*,† | 409.5 ± 63.9*,† | 428.0 ± 77.6*,† | 398.3 ± 101.0*,‡ | 380 ± 86.1§,‡ |
FEV1 (L) | 2.02 ± 7.6 | 2.33 ± 0.7*,† | ||||
MMEV (L/s) | 2.52 ± 1.3 | 3.12 ± 1.3*,† | ||||
Eosinophil count (/μL) | 608 ± 493.1 | 516 ± 522.1§,‡ | 453.9 ± 313.1§,‡ | 410 ± 299.0*,‡ | ||
TSIgE (IU/mL) | 1366 ± 1934.6 | 1395 ± 1563.7§,‡ | 1502.82 ± 2184.0§,‡ | 1440 ± 2084.4§,‡ | ||
IFN-γ (pg/mL) | 3.55 ± 2.2 | 4.22 ± 3.8§,‡ | 4.58 ± 2.8*,† | 4.67 ± 0.5*,‡ | ||
IL-4 (pg/mL) | 0.04 ± 0.039 | 0.08 ± 0.05*,‡ | 0.09 ± 0.03*,† | 0.1 ± 0.04*,† | ||
TGF-β1 (pg/mL) | 54,396 ± 6908 | 50,720 ± 7111.4*,‡ | 38,066 ± 9279||,‡ | 48,271 ± 9634||,‡ | ||
Placebo Group | Single BCG Group | |||||
PEFR (L/min) | 360 ± 53.3 | 343 ± 67.4§,† | 325 ± 63.8*,† | 315.50 ± 72.9*,† | 371 ± 73.98§,‡ | 346 ± 95.8§,‡ |
FEV1 (L) | 2.04 ± 0.65 | 1.64 ± 0.5*,† | ||||
MMEV (L/s) | 2.51 ± 1.2 | 2.01 ± 1.95*,† | ||||
Eosinophil count (/μL) | 649 ± 580.7 | 393 ± 358.4*,‡ | 569 ± 553.7§,‡ | 593 ± 582§,‡ | ||
Total IgE (IU/mL) | 887 ± 794.4 | 1053 ± 863.2§,‡ | 927 ± 1076.3§,‡ | 791 ± 1094.3§,‡ | ||
IFN-γ (pg/mL) | 3.65 ± 1.8 | 3.85 ± 1.95§,‡ | 5.25 ± 0.90*,† | 4.81 ± 1.30*,‡ | ||
IL-4 (pg/mL) | 0.08 ± 0.13 | 0.08 ± 0.11§,‡ | 0.16 ± 0.09*,† | 0.16 ± 0.13*,† | ||
TGF-β1 (pg/mL) | 53,910 ± 7525 | 51,480 ± 6084.9§,‡ | 40,853 ± 12,772||,‡ | 45,942 ± 9453||,‡ |